Sinco Pharmaceuticals publishes 2025 annual report

PUBT·04/20/2026 10:51:49

Listen to the news

Sinco Pharmaceuticals annual report for year ended Dec. 31, 2025 flagged weaker demand and sharper price pressure in China blood-products market, weighing on human albumin solution sales.
Group shifted commercial focus toward deeper hospital coverage, with increased participation in volume-based procurement and alliance tenders to defend market position.
Medical aesthetics pipeline advanced, with Girl Needle clinical summary completed and launch registration filed with National Medical Products Administration in Dec. 2025.
Cold-chain and supply-chain platform in Chengdu continued full operation, with management targeting scale-up and efficiency gains via digital supply-chain upgrades.
Board proposed final dividend of HKD 3.4 million, or HK 0.167 cents per share, subject to shareholder approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinco Pharmaceuticals Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260420-12112472), on April 20, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English